Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? So please join us as we prepare with a few cups of stimulation — our choice today is apple cider donut — and remember, no prescription is required. Meanwhile, here are some items of interest to help you along. Hope your day is smashing and, as always, do keep in touch …
Novartis (NVS) offered $3.9 billion in cash for Advanced Accelerator Applications (AAAP), providing a platform in radiopharmaceuticals that treat tumors. Last August, European regulators approved a ground-breaking, gene-modifying leukemia treatment developed by AAA, which hopes to win approval from the U.S. Food and Drug Administration in early 2018. Two years ago, Novartis purchased the GlaxoSmithKline (GSK) commercial cancer portfolio.
About the Author Reprints
